| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Renee P Tannenbaum is Director at ANIP and has filed Form 4s across 2 companies. Renee P Tannenbaum's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $2.2M at current prices.
Historically, Renee P Tannenbaum's trades have earned a middling insider score of 55/100 across 4 rated trades. Over a 12-month horizon, 66.7% of those trades were profitable, with an average 12-month return of -5.8%.
The biggest single holding is ANIP (~$2.1M) as Director. The ANIP filings lean toward selling, a net 3,800 shares.
Renee P Tannenbaum has 15 Form 4 filings on record from June 2021 to June 2026, across 2 companies: Director at Cardiff Oncology (CRDF), 2021–2026; Director at ANI Pharmaceuticals (ANIP), 2022–2026.
The 16 reported transactions were 6 option or other derivative awards, 5 stock awards, 3 open-market purchases and 2 open-market sales.
Counted by filing, the open-market trades come to 2 purchases worth about $51K and 2 sales worth about $274K.
The largest open-market purchase was 10,000 shares of CRDF at an average $3.42 on December 12, 2024, about $34K. Twelve months later CRDF was down 27%.
The largest open-market sale was 1,800 shares of ANIP at an average $81.15 on December 5, 2025, about $146K.
Neither of the two sales since April 2023 was marked as made under a Rule 10b5-1 trading plan.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 5, 2025 | ANIP Ani Pharmaceuticals Inc | Director | Sell | 1,800 | $81.15 | $146,070.00 | -6.7% | -7.5% | - | |
| Dec 12, 2024 | CRDF Cardiff Oncology, Inc. | Director | Buy | 10,000 | $3.42 | $34,224.00 | +100.0% | +26.9% | -26.9% | |
| May 16, 2024 | ANIP Ani Pharmaceuticals Inc | Director | Sell | 2,000 | $63.87 | $127,740.00 | -9.9% | -7.2% | -5.9% | |
| Sep 15, 2022 | CRDF Cardiff Oncology, Inc. | Director | Buy | 10,000 | $1.72 | $17,168.00 | New | -15.6% | +3.6% |